Scientists have developed an advanced multi-organ model to deepen the understanding of the gut-brain connection in ...
Gain Therapeutics' GT-02287 shows promise in treating Parkinson's disease, with positive results and potential for market ...
Researchers have uncovered a new understanding of levodopa-induced dyskinesia, a common side effect in Parkinson’s patients, ...
Hosted on MSN27d
Early Research Points to Possible New Parkinson's DrugCatching and treating Parkinson's disease early is crucial ... However, treating the Parkinson's-model mice with PNA5 appeared to lower the animals' blood levels of the inflammatory chemical.
News Medical on MSN6d
Could autophagy enhancement slow aging and combat Alzheimer's?Aging involves gradual functional decline across various biological systems, including impaired cellular mechanisms such as ...
IRX-4204 is under clinical development by Io Therapeutics and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition ...
An audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. A replay of the session will be available later that day. About Anavex Life Sciences Corp.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback